Meeting
2023 ASCO Annual Meeting
Alliance A021804: A prospective, multi-institutional phase II trial evaluating temozolomide versus temozolomide and olaparib for advanced pheochromocytoma and paraganglioma.
Authors
Jaydira Del Rivero
National Cancer Institute/National Institutes of Health, Bethesda, MD
Jaydira Del Rivero , Kimberly Perez , Susan Michelle Geyer , Maged F. Khalil , Aishwarya Vijendran , Andrea Kordaris-Corkill , Ardaman Shergill , Kristen Renee Spencer , Heloisa P. Soares , Charles D. Lopez , Andrew B. Nixon , Amylou C. Dueck , Jeffrey A. Meyerhardt , Eileen Mary O'Reilly
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Neuroendocrine/Carcinoid
Clinical Trial Registration Number
NCT04394858
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS4191)
DOI
10.1200/JCO.2023.41.16_suppl.TPS4191
Abstract #
TPS4191
Poster Bd #
502a
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.
First Author: Matthew Ingham
Poster
2014 ASCO Annual Meeting
Preclinical evaluation of PARP inhibitors in combination with DNA-damaging agents in a Ewing sarcoma orthotopic xenograft model.
First Author: Elizabeth Stewart
Poster
2023 ASCO Annual Meeting
Phase II trial of combination pembrolizumab, olaparib, and temozolomide for patients with recurrent glioma.
First Author: Lauren Schaff